ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2020

Strong sales growth during 2020; Zinzino group revenue increased with a total of 44% in Q4 and 48% for the full year 2020, compared with the previous year.

The revenue in December for Zinzino's sales markets increased by 77% to SEK 127.9 (72.3) million due to strong growth in many regions and countries. Faun Pharma's external sales increased by 158% and amounted to SEK 6.2 (2.4) million. Overall, the Group increased revenues by 80% to SEK 134.1 (74.7) million compared with the previous year.

The fourth quarter of 2020 became the strongest quarter in the history of the company. The Zinzino based revenue in October - December increased 43% to SEK 323.9 (226.7) million compared with the previous year. Total group revenue increased 44% to SEK 341.4 (236.3) million.

Accumulated revenue for January – December 2020 increased by 48% to SEK 1139.6 (770.6) million.

Revenues distributed as follows:

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 09:00 the 7th of January 2021.

Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market.